


Amendments To The Claims:


This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously presented) A process for preparing a monohydrochloride salt of compound (I)



wherein \*C and \*\*C denote asymmetric carbon atoms, which process comprises the steps of:


- a) contacting a compound of formula (II):




wherein P<sup>1</sup> represents a hydroxyl protecting group, and P<sup>2</sup> and P<sup>3</sup> each independently represents hydrogen or a protecting group;  
with a weak acid, to effect selective protonation;

- b) contacting the product of (a) with a source of chloride ions, to effect anion exchange;  
c) deprotecting to remove P<sup>1</sup>, and where necessary P<sup>2</sup> and P<sup>3</sup>;  
d) isolating compound (I) as the monohydrochloride; and optionally  
e) crystallizing or recrystallizing compound (I).

2. (Original) A process according to claim 1, wherein the compound of formula (I) is the compound (Ia):



and the compound of formula (II) is the compound (IIa)



wherein P<sup>1</sup> is as defined in claim 1.

3. (Previously presented) A process according to claim 1 wherein the weak acid is acetic acid.
4. (Previously presented) A process according to claim 1 wherein the group P<sup>1</sup> represents benzyl.
5. (Previously presented) A process according to claim 1 wherein the source of chloride ions is sodium chloride.
6. (Previously presented) Crystalline monohydrochloride salt of the compound of formula (Ia) prepared by a process according to claim 1.
7. (Previously presented) Crystalline (Ia) monohydrochloride according to claim 6 wherein the product of said process is characterised by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in Fig. I.

8. (Currently amended) Crystalline [[*(Ia)*]] *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound *(Ia)*) monohydrochloride which is characterised by a differential scanning calorimetry trace which shows an absence of discernable endothermic features below about 125°C.

9. (Currently amended) Crystalline Compound *(Ia)* monohydrochloride according to claim 8 which is characterised by a differential scanning calorimetry trace which shows an absence of discernable endothermic features below about 125 °C and an onset of significant endothermic heat flow at about 229 °C.

10. (Currently Amended) Crystalline Compound *(Ia)* monohydrochloride according to claim 8 which is characterised by a differential scanning calorimetry trace which shows an absence of discernable endothermic features below about 125 °C, two or more minor endothermic events between about 130°C and about 180°C and an onset of significant endothermic heat flow at about 229°C.

11. (Currently amended) Crystalline Compound *(Ia)* monohydrochloride according to claim 10 wherein said minor endothermic events occur at about 133 °C, at about 151°C and at about 170°C.

12. (Currently amended) Form 2 crystalline [[*(Ia)*]] *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound *(Ia)*) monohydrochloride in substantially pure form.

13. (Currently amended) A process for obtaining Form 2 crystalline [[*(Ia)*]] *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound *(Ia)*) monohydrochloride in substantially pure form which process comprises:

Ba) forming a mixture of *N*-{2-[4-((*R*)-2-hydroxy-2-

phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride in an aqueous organic solvent, by contacting said monohydrochloride with said solvent and heating in a range from about 60 °C to about 70 °C;

Bb) adjusting the temperature of said mixture in the range from about 52°C to about 58°C;

Bc) seeding said mixture with Form 2 crystals;

Bd) cooling said mixture to a temperature in the range from about 15 °C to 25 °C;

Be) heating said mixture to a temperature in the range from about 47 °C to about 52 °C;

Bf) repeating steps Bd) and Be) to obtain the desired Form 2.

14. (Currently Amended) A method for the ~~prophylaxis or~~ treatment of a clinical condition in a mammal for which a selective adrenoreceptor agonist is indicated, wherein the condition is asthma or chronic obstructive pulmonary disease (COPD), the method comprising ~~which comprises~~ administering a therapeutically effective amount of Form 2 crystalline [[Ia]] N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound Ia) monohydrochloride.

15-16. (Cancelled)

17. (Currently amended) A pharmaceutical formulation comprising Form 2 crystalline [[Ia]] N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound Ia) monohydrochloride and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

18. (Currently amended) A combination comprising Form 2 crystalline [[Ia]] N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound Ia) monohydrochloride and one or more other therapeutic ingredients.

19. (Original) A combination according to claim 18 wherein the other therapeutic ingredient is a PDE4 inhibitor or an anticholinergic or a corticosteroid.
20. (Currently Amended) A combination according to claim 18 comprising Form 2 crystalline [(Ia)] *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound Ia) monohydrochloride and 6 $\alpha$ ,9 $\alpha$ -difluoro-17 $\alpha$ -(2-furanylcarbonyl)oxy]-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-fluoromethyl ester.
21. (Currently Amended) A combination according to claim 18 comprising Form 2 crystalline [(Ia)] *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound Ia) monohydrochloride and 6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-17 $\alpha$ -(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-fluoromethyl ester.
22. (Previously presented) A process according to claim 13, wherein said Ba) step comprises heating the mixture to a temperature of about 65°C.
23. (Previously presented) A process according to claim 13, wherein said Bb) step comprises adjusting the temperature of said mixture from about 52°C to about 55°C.
24. (Previously presented) A method according to claim 14, wherein the mammal is a human.
25. (Previously presented) A method according to claim 14, wherein the clinical condition is asthma.
26. (Previously presented) A method according to claim 14, wherein the clinical condition is COPD.